The tweet was deleted by the author.
But we saved everything 🙂.
NeuroPace Inc has highlighted a patient's preference for the RNS System over the VNS device for seizure management. The patient reported that the RNS System's ability to stop seizures at their source made it a more attractive option compared to the VNS, which requires detection of symptoms before activation.
This distinction in intervention timing may influence patient choices and clinical decision-making for those seeking effective seizure control. NeuroPace Inc continues to develop neurostimulation therapies aiming to improve quality of life for individuals with epilepsy.
NeuroPace Inc recently hosted a symposium on responsive thalamic neuromodulation for drug-resistant epilepsy at ASSFN2026, drawing strong interest from the clinical community, according to a previous report. The company also presented early Nautilus study results and discussed LGS device feasibility during the ASSFN breakfast session with leading doctors, as noted in an earlier article. These events reflect continued engagement with neuromodulation research in epilepsy treatment.